Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 2
2(50.0%)
4Total
N/A(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07525063Not ApplicableNot Yet Recruiting

Pain & Reward Neuromodulation of CNS Circuits

Role: collaborator

NCT06946940Phase 2Recruiting

Biosignature of the Response to Treatment With Cannabis Oil in Individuals With Fibromyalgia

Role: collaborator

NCT04263454Phase 2Completed

The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia

Role: collaborator

NCT00568555Not ApplicableCompleted

Effects of Low Dose Naltrexone in Fibromyalgia

Role: collaborator

All 4 trials loaded